On July 15, 2026, Regentis Biomaterials Ltd. announced it received European regulatory approval for a new GelrinC manufacturing process. This process increases production yield by 400% and supports the company's upcoming European commercial launch. The company operates in the biomaterials industry and develops medical-grade materials.
